- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00229775
Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: In the Philippines, close to 11 million people in 65 provinces are at risk for acquiring malaria infections. It is still one of the ten leading causes of morbidity nationwide. Each day, roughly 150-200 people fall ill with malaria. In the past 40 years, the mortality rate stabilized at around 2/100,000 population. Of those people who have malaria, approximately 1% die per year. Malaria remains one of the major causes of death in provinces such as Palawan, Isabela, Tawi-tawi, Sulu and Butuan City. Approximately 70% of all malaria in the Philippines is Plasmodium falciparum with the remaining species being P. vivax.
Recently the Department of Health (DOH) instituted a change in the national antimalarial drug guidelines changing from using chloroquine (CQ) and sulfadoxine pyrimethamine (SP) monotherapy as first and second line drugs, respectively, to a combined chloroquine plus sulfadoxine-pyrimethamine as first-line treatment, and artemether-lumefantrine (Coartem) as second line treatment. This change was made due to increasing levels of drug resistance to the previous first and second-line therapies. In order to have an improved understanding of the trends of antimalarial drug resistance in the Philippines, the DOH is initiating a sentinel surveillance system for monitoring of antimalarial drug resistance. Three sites have been selected to be representative of the country.
Objective: To establish a sentinel surveillance system to assess the efficacy of chloroquine plus sulfadoxine-pyrimethamine versus artemether + lumefantrine for the treatment of uncomplicated P. falciparum infections in three areas of the Republic of the Philippines.
Methods: An in vivo antimalarial drug efficacy trial will be conducted in three areas of the Philippines. Subjects > 6 months of age with parasitologically confirmed, uncomplicated P. falciparum infections will be recruited. Patients will be treated with single dose SP (25 mg/kg of the sulfadoxine component in a single dose) plus CQ (25 mg/kg over three days) or artemether + lumefantrine (twice daily) over 3 days. Patients will be randomly assigned one of the two drugs regimens. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy. Results from this study will be used to assist the DOH in assessing their national malaria treatment policy for P. falciparum malaria.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kalinga Province
-
Tabuk, Kalinga Province, Philippines
- Kalinga Health Center
-
-
Mindinao
-
Davao City, Mindinao, Philippines
- Davao Health Center
-
-
Palawan
-
Puerto Princesa, Palawan, Philippines
- Palawan Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Weight > 10 kg;
- Documented fever (axillary temperature >37.5oC) and/or a history of fever during the previous 24 hours in the absence of another obvious cause of fever (such as pneumonia, measles, otitis media);
- Monoinfection with P. falciparum between 1,000 and 100,000 asexual parasites/µl as determined by microscopic examination of thick, or thick and thin peripheral blood smears;
- Informed consent from the patient or parent/guardian (in the case of children),assent from child (ages 8 -17 years inclusive);
- Willingness on the part of the patient to return to the clinic for regular check-ups during the 28-day follow-up period.
Exclusion Criteria:
1. Danger signs: unable to drink or breastfeed; vomiting (more than twice in the previous 24 hours); recent history of convulsions (one or more in the previous 24 hours); impaired consciousness; unable to sit or stand; 2. Severe Manifestations of P. falciparum malaria in adults and children (World Health Organization criteria)
- Prostration (inability to sit unassisted [children], extreme weakness [adults])
- Impaired consciousness (Blantyre coma scale [children], Glascow coma scale [adults])
- Respiratory distress (sustained nasal flaring, indrawing, Kussmaul breathing)
- Multiple convulsions (³2 convulsions/24 hour period)
- Circulatory collapse (hypotension and poor perfusion)
- Pulmonary edema
- Abnormal bleeding
- Jaundice
- Hemoglobinuria
- Severe anemia (Hb < 5 gm/dL)
- Hypoglycemia (blood glucose < 2.2 mmol/L [<40 mg/dL])
- Acidosis (bicarbonate <15 mmol/L)
- Hyperparisitemia (level varies with endemicity)
- Renal impairment (urine output < 12 mL/kg/24 hours) 3. Other underlying chronic or severe diseases (e.g., cardiac, renal, hepatic diseases, HIV/AIDS, malnutrition); 4. History of hypersensitivity reactions to any of the drugs being tested or used as alternative treatment: sulfonamides, chloroquine, artemisinins, artemether, lumefantrine, quinine or tetracycline/clindamycin; 4. Pregnancy (history of pregnancy or a positive urine pregnancy test); 5. Women who are breast feeding children less than 8 weeks of age. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Clinical cure
|
Secondary Outcome Measures
Outcome Measure |
---|
Hemoglobin levels
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Dorin Bustos, MD, PhD, RITM, DOH, Philippines
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Malaria, Falciparum
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Folic Acid Antagonists
- Anti-Infective Agents, Urinary
- Renal Agents
- Chloroquine
- Artemether
- Pyrimethamine
- Sulfadoxine
- Fanasil, pyrimethamine drug combination
Other Study ID Numbers
- CDC-NCID-3913
- U30/CCU317876-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine
-
Centers for Disease Control and PreventionMalaria Research and Training Center, Bamako, MaliCompleted
-
Institute of Tropical Medicine, BelgiumTerminatedPlasmodium Falciparum MalariaZambia
-
University of Cape TownWorld Health Organization; Medical Research Council, South Africa; Global FundCompleted
-
Centers for Disease Control and PreventionUnited States Agency for International Development (USAID)CompletedMalaria (Uncomplicated)Tanzania
-
University of MelbourneUniversity of Barcelona; Papua New Guinea Institute of Medical Research; The... and other collaboratorsCompletedSexually Transmitted Infections | Malaria in Pregnancy | AnaemiaPapua New Guinea
-
London School of Hygiene and Tropical MedicineDBL -Institute for Health Research and Development; Uganda AIDS CommissionCompletedHIV Infections | Malaria in PregnancyUganda
-
University of OxfordSanaria Inc.; KEMRI-Wellcome Trust Collaborative Research Program; Kenya Medical...Active, not recruitingMalaria,FalciparumKenya
-
PfizerLondon School of Hygiene and Tropical Medicine; Medicines for Malaria VentureTerminatedIntermittent Preventive Treatment In Pregnancy (IPTp)Malawi, Benin, Kenya, Tanzania, Uganda
-
London School of Hygiene and Tropical MedicineMedical Research Council; National Malaria Control Programme, The GambiaCompleted
-
Institut de Recherche pour le DeveloppementCompleted